Ask anyone in the hemophilia community about summer camp, and you'll see an immediate reaction—a big grin, a sparkle in their eyes, and the immediate re-telling of camp stories.

Wyeth recognizes the contribution that the summer camp experience makes to children in the bleeding disorder community, and is proud to be the founding and exclusive sponsor of NACCHO (North American Camping Conference of Hemophilia Organizations). NACCHO is the only conference dedicated to sharing best practices for bleeding disorders summer camps and is conducted by the Hemophilia Association of Phoenix, Arizona.

NACCHO and Wyeth also support the health care professionals that are a mainstay of the summer camp experience. In 2006, a special nursing task force of NACCHO, in association with the Nursing Working Group of the National Hemophilia Foundation (NHF), completed guidelines for camp health centers. The guidelines were endorsed by the NHF Medical and Scientific Advisory Council and are available from www.NACCHO.com, or at the NHF Web site, www.hemophilia.org.

NACCHO/Wyeth Cup Awarded to Camp Ailihpomeh for Outstanding CIT Program

At the fourth annual North American Camping Conference of Hemophilia Organizations, Camp Ailihpomeh ("hemophilia" spelled backwards) of Texas won first prize for its "Leadership Program" counselor in training (CIT) course. Camp Ailihpomeh's program provides training and service opportunities for teenagers who have graduated from camp and is an introduction to the camp's CIT program.

Ed Kuebler, center, from Camp Ailihpomeh accepts the NACCHO/Wyeth Cup from Mike Rosenthal, left, NACCHO chair, and David Dubinski of Wyeth.

Camp Bold Eagle of Michigan won second place for its counselor in training program, in which CITs were asked to organize a camp-wide orientation session to promote team-building and creativity. Camp E Ho'omana Kakou of Hawaii won third place for its "Being Empowered Together" program, which introduces CITs to career planning and the college environment.

In addition to NACCHO, Wyeth provides other assistance to summer camps:

• Financial assistance to be used at the discretion of the camps to fund camp scholarships, as well as other special programs.
  
  
• Product donations of BeneFIX and ReFacto to camps. In 2005, Wyeth helped 26 bleeding disorder summer camps with product donations. To apply for a product donation for the 2007 camping season, click here. (Application must be completed by the camp medical director.)

This document is in PDF (portable document format). PDF files require Adobe® Reader®; click here to download this free program.

Indication
BeneFIX is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or Christmas disease), including control and prevention of bleeding in surgical settings. BeneFIX is not indicated for the treatment of other factor deficiencies (eg, factors II, VII, VIII and X) nor the treatment of hemophilia A patients with inhibitors to factor VIII, nor the reversal of coumarin-induced anticoagulation, nor the treatment of bleeding due to low levels of liver-dependent coagulation factors.

Important Safety Information

	•	As with the intravenous administration of any protein product, common adverse reactions may include headache, fever, chills, flushing, nausea, vomiting, or tiredness.
	•	BeneFIX may be contraindicated in patients with a known history of hypersensitivity to hamster protein.
	•	Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported for all factor IX products. Patients should be informed of the early symptoms and signs of hypersensitivity reactions. Patients should discontinue use of the product and contact their health care provider immediately and/or seek emergency care if any hypersensitivity reactions occur.

Please see BeneFIX Prescribing Information

Indication
ReFacto is indicated for the control and prevention of hemorrhagic episodes and for surgical prophylaxis and for short-term routine prophylaxis to reduce the frequency of spontaneous bleeding episodes in patients with hemophilia A. The effect of regular routine prophylaxis on long-term morbidity and mortality is unknown.

Important Safety Information

	•	As with the intravenous administration of any protein product, adverse reactions may include headache, fever, chills, flushing, nausea, vomiting, tiredness, or symptoms of allergic reactions.
	•	The remote possibility exists for hypersensitivity to non-human mammalian proteins. Known hypersensitivity to mouse or hamster proteins may be a contraindication to the use of ReFacto.
	•	Allergic reactions such as hives, itching, difficulty breathing, rapid heart rate, light-headedness and anaphylaxis have been reported for all factor VIII products. Patients should discontinue use of the product and contact their health care provider immediately and/or seek emergency care if any of these symptoms occur.

Please see ReFacto Prescribing Information

The health information contained herein is provided for educational purposes only and is not meant to replace personal discussions between health care providers and patients. All decisions about patient care must be made with a health care provider who can assess the special needs of each individual patient.